EHA
June 10, 2022
European Hematology Association (EHA) Hybrid Congress, June 9-17, 2022
Year
2022
Target
RVU120 (CDK8/CDK19), RVU 305 (PRMT5), PIM/FLT3
Assets in this page
Download assets
- pdf file
CLI120-001 Phase1b Dose Escalation Study of RVU120 in Patients with AML or High-Risk MDS Safety and Efficacy Data Update
Download - pdf file
RVU120, a small molecule inhibitor of CDK8/19 kinases, enhances rituximab-driven NK cells-mediated cytotoxicity both in vitro and in vivo
Download - pdf file
Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP deleted cancers
Download